{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
  "id": "02964020",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
  "summary": "### **AFT Pharmaceuticals \u2013 June Quarter FY26 Investor Update Summary**  \n\n- **Combogesic IV (Maxigesic IV) launched in Canada** \u2013 Sales commence as part of North American expansion strategy.  \n- **Extended US licensing agreement with Hikma Pharmaceuticals** \u2013 Covers both Combogesic IV and Rapid tablet, restructuring profit-sharing to direct quarterly payments.  \n- **R&D pipeline progress**:  \n  - **Antibiotic eyedrop**: Pre-IND filed with FDA, IND targeted by year-end.  \n  - **Strawberry Birthmarks topical**: Pre-IND filing planned this year.  \n  - **Novel iron injection**: IND filing expected by year-end.  \n- **Paediatric Maxigesic IV study in preparation** \u2013 Aims to expand approved patient population.  \n- **Five out-licensing deals completed** \u2013 Additional agreements under negotiation.  \n\n**No capital raising, financial figures, or material trading-sensitive dates identified.**",
  "usage": {
    "prompt_tokens": 2426,
    "completion_tokens": 199,
    "total_tokens": 2625,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T21:49:09.176295"
}